ClinicalTrials.gg
CompletedNCT02040766Updated Nov 9, 2021Results posted

A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma

A Phase 3 interventional study of Beclomethasone dipropionate BAI and Placebo BAI in Asthma, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 102 sites in 5 countries. Open to participants aged 4 Years to 11 Years. Per ClinicalTrials.gov, last updated 2021-11-09.

Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
628
Allocation
Randomized
Ages
4 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing beclomethasone in Asthma — none open to participants now, none under way, none of them phase 3. Beclomethasone · Asthma.

Enrollment
6th of 40
628 · median 67
Started
2013
with 4 others
Phase 3
20 of 40
none open now
Registered
26th of 40
by date
Lead sponsor
7 of 40
Teva Branded Pharmaceutical Products R&D, Inc.

Among the 40 studies testing beclomethasone in Asthma, this one is the 6th largest by enrollment, is one of 5 that started in 2013, is one of 20 in phase 3, and was the 26th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 40 studies testing beclomethasone in Asthma is open now. The open studies under Asthma, anywhere →

About beclomethasone

Beclomethasone: first FDA approval 1976 (VANCERIL), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 4 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing beclomethasone in Asthma as a file.
02

Study summary

This randomized, double-blind, double-dummy, placebo-controlled, parallel-group, 12-week study will evaluate the efficacy and safety of beclomethasone dipropionate (80 or 160 mcg/day) administered via breath-actuated inhaler (BAI) and metered-dose inhaler (MDI) in pediatric patients 4 through 11 years of age with persistent asthma, compared with placebo.

Patients took 1 inhalation (with assistance from parents/guardians/caregivers, as needed) from each of 2 devices (BAI device followed by MDI device in that order) twice daily as per the double-dummy study design: 1 BAI treatment or placebo device and 1 MDI treatment or placebo device for a total of 2 inhalations each time.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • asthma
  • breath-actuated inhaler
  • metered dose inhaler
04

Who can participate

Ages eligible
4 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • Asthma diagnosis: The patient has a diagnosis of asthma as defined by the National Institute of Health (NIH). The asthma diagnosis has been present for a minimum of 3 months and has been stable (defined as no exacerbations and no changes in medication) for at least 30 days before screening visit
  • Severity of disease: The patient has persistent asthma, with a (FEV1) 40% to 90% of the value predicted for age, height, and sex at screening visit (SV)
  • Current asthma therapy: The patient is currently being treated with 1 of the following: 1) a stable daily dosage of an inhaled (ICS) in the range of 88-176 mcg/day of fluticasone propionate (or equivalent) for a minimum of 4 weeks (28 days) before screening visit 2) a stable daily dosage of non-corticosteroid therapy 3) a daily dose of ICS plus a long-acting beta2-agonist (LABA) (at a dose less than or equivalent to fluticasone propionate 100 mcg/salmeterol 50 mcg twice daily)
  • Reversibility of disease: The patient has demonstrated at least 12% reversibility of FEV1 within 30 minutes after 2-4 inhalations of albuterol/salbutamol hydrofluoroalkane (HFA) MDI (90 mcg ex-actuator) or equivalent at screening visit or on retesting.
  • Other criteria apply, please contact the investigator for more information

Exclusion criteria

Exclusion Criteria:

  • The patient has a history of life-threatening asthma, defined for this protocol as an asthma episode that required intubation and/or was associated with hypercapnia, respiratory arrest, or hypoxic seizures.
  • The patient is pregnant or lactating, or plans to become pregnant during the study period or for 30 days after the patient's last study-related visit (for eligible patients only, if applicable). Any patient becoming pregnant during the study will be withdrawn from the study.
  • The patient has a known to any or any of the in the study drug or rescue medication formulation.
  • The patient has used tobacco products within the past year (eg, cigarettes, cigars, chewing tobacco, or pipe tobacco, as applicable).
  • The patient has had an asthma exacerbation requiring oral corticosteroids within 30 days before screening visit, or has had any hospitalization for asthma within 2 months before screening visit.
  • The patient has historical or current evidence of a disease. Significant disease is defined as any disease that in the medical judgment of the investigator would put the safety of the patient at risk through participation or that could affect the efficacy or safety analysis if the disease/condition worsened during the study.
  • Other criteria apply, please contact the investigator for more information
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
628 participants (actual)

Study arms

  • Experimental
    BDP 80 mcg BAI

    Beclomethasone dipropionate (BDP) was administered via a breath-actuated inhaler (BAI) twice daily (40 mcg twice a day). Placebo MDI twice daily for blinding. Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study.

    Drug: Beclomethasone dipropionate BAI · Drug: albuterol/salbutamol 90 mcg · Drug: Placebo MDI

  • Experimental
    BDP 160 mcg BAI

    Beclomethasone dipropionate (BDP) was administered via a breath-actuated inhaler (BAI) twice daily (80 mcg twice a day). Placebo MDI twice daily for blinding. Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study.

    Drug: Beclomethasone dipropionate BAI · Drug: albuterol/salbutamol 90 mcg · Drug: Placebo MDI

  • Active comparator
    BDP 80 mcg MDI

    Beclomethasone dipropionate (BDP) was administered via a metered-dose inhaler (MDI) twice daily (40 mcg twice a day). Placebo BAI twice daily for blinding. Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study.

    Drug: Placebo BAI · Drug: albuterol/salbutamol 90 mcg · Drug: Beclomethasone dipropionate MDI

  • Active comparator
    BDP 160 mcg MDI

    Beclomethasone dipropionate (BDP) was administered via a metered-dose inhaler (MDI) twice daily (80 mcg twice a day). Placebo BAI twice daily for blinding. Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study.

    Drug: Placebo BAI · Drug: albuterol/salbutamol 90 mcg · Drug: Beclomethasone dipropionate MDI

  • Placebo comparator
    Placebo BAI and MDI

    Placebo was administered via breath-actuated inhaler (BAI) twice daily. Additionally placebo was administered via metered-dose inhaler (MDI) twice daily. Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study.

    Drug: Placebo BAI · Drug: albuterol/salbutamol 90 mcg · Drug: Placebo MDI

Interventions

  • Beclomethasone dipropionate (BDP), was delivered by a single inhalation using a breath-actuated inhaler (BAI) at levels of 40 mcg or 80 mcg per inhalation, twice each day.

    Also known as: BDP, breath-actuated inhaler

  • DrugPlacebo BAI

    Placebo was delivered by a single inhalation using a breath-actuated inhaler (BAI) twice each day.

    Also known as: breath-actuated inhaler

  • Drugalbuterol/salbutamol 90 mcg

    Drug page: Albuterol

    Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI \[90 mcg ex-actuator\] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period.

    Also known as: bronchodilators

  • Beclomethasone dipropionate (BDP), was delivered by a single inhalation using a metered-dose inhaler (MDI) at levels of 40 mcg or 80 mcg per inhalation, twice each day.

    Also known as: BDP, metered-dose inhaler, QVAR®

  • DrugPlacebo MDI

    Placebo was delivered by a single inhalation using a metered-dose inhaler (MDI) twice each day.

06

What researchers measure

Primary outcomes

  1. Standardized Baseline-adjusted Trough Morning Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Effect Curve From Time 0 to 12 Weeks (AUEC(0-12wk))

    Trough morning FEV1 measurements were taken pre-dose and pre-rescue bronchodilator treatment for asthma. Baseline was defined as baseline trough morning percent predicted FEV1. Pulmonary function measurements (including FEV1) were obtained electronically by spirometry. All pulmonary function test data were submitted to a central reading center for evaluation. The highest ('best attempt') FEV1 value from 3 acceptable and 2 repeatable maneuvers (maximum of 8 attempts) was used.

    Time frame: Day 1 (baseline), Weeks 2, 4, 8, 12

Secondary outcomes

  1. Change From Baseline in Weekly Average of Daily Trough Morning Peak Expiratory Flow (PEF) Over the 12-week Treatment Period

    The analysis of change from baseline in weekly average of daily trough morning (pre-dose and pre-rescue bronchodilator) PEF calculated across the 12-week treatment period was performed using a mixed model for repeated measures (MMRM) with effects due to baseline weekly average of daily trough morning PEF.

    Time frame: Day 1 (baseline), weeks 1-12

  2. Change From Baseline in Weekly Average of Daily Evening Peak Expiratory Flow (PEF) Over the 12-week Treatment Period

    The analysis of change from baseline in the weekly average of daily evening PEF across the 12-week treatment period was performed using a mixed model for repeated measures (MMRM) with effects due to baseline weekly average of daily evening PEF.

    Time frame: Day 1 (baseline), weeks 1-12

  3. Change From Baseline in the Weekly Average of Total Daily (24-hour) Use of Albuterol/Salbutamol Inhalation Aerosol (Number of Inhalations) Over Weeks 1-12

    The change from baseline in the weekly average of total daily (24-hour) use of albuterol/ salbutamol inhalation aerosol (number of inhalations) across the 12 weeks was analyzed using a mixed model for repeated measures (MMRM).

    Time frame: Day 1 (baseline), weeks 1-12

  4. Change From Baseline in the Weekly Average of the Total Daily Asthma Symptom Score Over Weeks 1-12

    The total daily asthma symptom score is the average of the daytime and nighttime scores analyzed using an mixed model for repeated measures (MMRM). Baseline was defined as the average of recorded morning and evening asthma symptom scores over the 7 days before randomization. Daytime Scores range from 0=No symptoms during the day to 5=Symptoms so severe that I could not go to work or perform normal daily activities; Nighttime Scores range from 0=No symptoms during the night to 4=Symptoms so severe that I did not sleep at all. The daily asthma symptom score was therefore 0 - 9 with 0=no symptoms during the day or night and 9=severe symptoms both day and night.

    Time frame: Day 1 (baseline), weeks 1-12

  5. Kaplan-Meier Estimates For Time to Withdrawal Due to Meeting Stopping Criteria for Worsening Asthma During the 12-week Treatment Period

    Time to withdrawal due to meeting stopping criteria was defined as number of days elapsed from the date of first dose of double-blind study treatment to the date of withdrawal due to meeting stopping criteria. Kaplan-Meier estimates (median and 95% CI of the median) are not applicable if the proportion of participants withdrawn is less than 0.5.

    Time frame: Day 1 to 12 weeks

07

Results

Posted Feb 12, 2018

Participant flow

Patients were screened at 123 centers in Croatia, Mexico, Poland, Ukraine, and the United States. The intent-to-treat (ITT) population included all randomly assigned patients

Participant flow — Overall Study
MilestonePlacebo BAI and MDIBDP 80 mcg BAIBDP 160 mcg BAIBDP 80 mcg MDIBDP 160 mcg MDI
Started127126125125125
Completed109116113112112
Not completed1810121313
Withdrew: Adverse event11102
Withdrew: Withdrawal by subject43232
Withdrew: Non-compliance01000
Withdrew: Protocol violation21230
Withdrew: Lost to follow-up41314
Withdrew: Not reported10000
Withdrew: Lack of efficacy63465

Outcome measures

PrimaryStandardized Baseline-adjusted Trough Morning Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Effect Curve From Time 0 to 12 Weeks (AUEC(0-12wk))

Trough morning FEV1 measurements were taken pre-dose and pre-rescue bronchodilator treatment for asthma. Baseline was defined as baseline trough morning percent predicted FEV1. Pulmonary function measurements (including FEV1) were obtained electronically by spirometry. All pulmonary function test data were submitted to a central reading center for evaluation. The highest ('best attempt') FEV1 value from 3 acceptable and 2 repeatable maneuvers (maximum of 8 attempts) was used.

Time frame:
Day 1 (baseline), Weeks 2, 4, 8, 12
Reported as:
Least squares mean · liters
Standardized Baseline-adjusted Trough Morning Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Effect Curve From Time 0 to 12 Weeks (AUEC(0-12wk))
litersPlacebo BAI and MDIBDP 80 mcg BAIBDP 160 mcg BAIBDP 80 mcg MDIBDP 160 mcg MDI
Standardized Baseline-adjusted Trough Morning Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Effect Curve From Time 0 to 12 Weeks (AUEC(0-12wk))2.62 ± 0.7445.43 ± 0.7423.25 ± 0.7323.54 ± 0.7343.71 ± 0.734
Statistical analysis
  • Placebo BAI and MDI vs BDP 80 mcg BAI · ANCOVA · p = 0.0063 (significance at 0.05.) · Mean difference (final values): 2.81 · 95% CI 0.796 to 4.821
  • Placebo BAI and MDI vs BDP 160 mcg BAI · ANCOVA · p = 0.5332 (significance at 0.05.) · Mean difference (final values): 0.63 · 95% CI -1.354 to 2.614
  • Placebo BAI and MDI vs BDP 80 mcg MDI · ANCOVA · p = 0.3649 (significance at 0.05) · Mean difference (final values): 0.92 · 95% CI -1.077 to 2.924
  • Placebo BAI and MDI vs BDP 160 mcg MDI · ANCOVA · p = 0.2823 · Mean difference (final values): 1.09 · 95% CI -0.902 to 3.088
SecondaryChange From Baseline in Weekly Average of Daily Trough Morning Peak Expiratory Flow (PEF) Over the 12-week Treatment Period

The analysis of change from baseline in weekly average of daily trough morning (pre-dose and pre-rescue bronchodilator) PEF calculated across the 12-week treatment period was performed using a mixed model for repeated measures (MMRM) with effects due to baseline weekly average of daily trough morning PEF.

Time frame:
Day 1 (baseline), weeks 1-12
Reported as:
Least squares mean · liters
Change From Baseline in Weekly Average of Daily Trough Morning Peak Expiratory Flow (PEF) Over the 12-week Treatment Period
litersPlacebo BAI and MDIBDP 80 mcg BAIBDP 160 mcg BAIBDP 80 mcg MDIBDP 160 mcg MDI
Change From Baseline in Weekly Average of Daily Trough Morning Peak Expiratory Flow (PEF) Over the 12-week Treatment Period4.3 ± 2.1115.6 ± 2.0812.8 ± 2.1211.9 ± 2.1110.8 ± 2.11
Statistical analysis
  • Placebo BAI and MDI vs BDP 80 mcg BAI · Mixed Models Analysis · p = 0.0001 · Mean difference (final values): 11.3 · 95% CI 5.58 to 17.06
  • Placebo BAI and MDI vs BDP 160 mcg BAI · Mixed Models Analysis · p = 0.0041 · Mean difference (final values): 8.5 · 95% CI 2.71 to 14.24
  • Placebo BAI and MDI vs BDP 80 mcg MDI · Mixed Models Analysis · p = 0.0103 · Mean difference (final values): 7.6 · 95% CI 1.79 to 13.35
  • Placebo BAI and MDI vs BDP 160 mcg MDI · Mixed Models Analysis · p = 0.0278 · Mean difference (final values): 6.5 · 95% CI 0.71 to 12.23
SecondaryChange From Baseline in Weekly Average of Daily Evening Peak Expiratory Flow (PEF) Over the 12-week Treatment Period

The analysis of change from baseline in the weekly average of daily evening PEF across the 12-week treatment period was performed using a mixed model for repeated measures (MMRM) with effects due to baseline weekly average of daily evening PEF.

Time frame:
Day 1 (baseline), weeks 1-12
Reported as:
Least squares mean · liters
Change From Baseline in Weekly Average of Daily Evening Peak Expiratory Flow (PEF) Over the 12-week Treatment Period
litersPlacebo BAI and MDIBDP 80 mcg BAIBDP 160 mcg BAIBDP 80 mcg MDIBDP 160 mcg MDI
Change From Baseline in Weekly Average of Daily Evening Peak Expiratory Flow (PEF) Over the 12-week Treatment Period1.4 ± 2.1113.1 ± 2.0911.4 ± 2.1211.3 ± 2.1210.1 ± 2.12
Statistical analysis
  • Placebo BAI and MDI vs BDP 80 mcg BAI · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 11.7 · 95% CI 5.96 to 17.45
  • Placebo BAI and MDI vs BDP 160 mcg BAI · Mixed Models Analysis · p = 0.0007 · Mean difference (final values): 10.0 · 95% CI 4.20 to 15.76
  • Placebo BAI and MDI vs BDP 80 mcg MDI · Mixed Models Analysis · p = 0.0008 · Mean difference (final values): 9.9 · 95% CI 4.11 to 15.68
  • Placebo BAI and MDI vs BDP 160 mcg MDI · Mixed Models Analysis · p = 0.0031 · Mean difference (final values): 8.7 · 95% CI 2.95 to 14.49
SecondaryChange From Baseline in the Weekly Average of Total Daily (24-hour) Use of Albuterol/Salbutamol Inhalation Aerosol (Number of Inhalations) Over Weeks 1-12

The change from baseline in the weekly average of total daily (24-hour) use of albuterol/ salbutamol inhalation aerosol (number of inhalations) across the 12 weeks was analyzed using a mixed model for repeated measures (MMRM).

Time frame:
Day 1 (baseline), weeks 1-12
Reported as:
Least squares mean · Number of inhalations
Change From Baseline in the Weekly Average of Total Daily (24-hour) Use of Albuterol/Salbutamol Inhalation Aerosol (Number of Inhalations) Over Weeks 1-12
Number of inhalationsPlacebo BAI and MDIBDP 80 mcg BAIBDP 160 mcg BAIBDP 80 mcg MDIBDP 160 mcg MDI
Change From Baseline in the Weekly Average of Total Daily (24-hour) Use of Albuterol/Salbutamol Inhalation Aerosol (Number of Inhalations) Over Weeks 1-12-0.36 ± 0.069-0.72 ± 0.068-0.50 ± 0.069-0.41 ± 0.069-0.54 ± 0.069
Statistical analysis
  • Placebo BAI and MDI vs BDP 80 mcg BAI · Mixed Models Analysis · p = 0.0002 · Mean difference (final values): -0.36 · 95% CI -0.548 to -0.174
  • Placebo BAI and MDI vs BDP 160 mcg BAI · Mixed Models Analysis · p = 0.1320 · Mean difference (final values): -0.14 · 95% CI -0.331 to 0.044
  • Placebo BAI and MDI vs BDP 80 mcg MDI · Mixed Models Analysis · p = 0.5866 · Mean difference (final values): -0.05 · 95% CI -0.240 to 0.136
  • Placebo BAI and MDI vs BDP 160 mcg MDI · Mixed Models Analysis · p = 0.0587 · Mean difference (final values): -0.18 · 95% CI -0.369 to 0.007
SecondaryChange From Baseline in the Weekly Average of the Total Daily Asthma Symptom Score Over Weeks 1-12

The total daily asthma symptom score is the average of the daytime and nighttime scores analyzed using an mixed model for repeated measures (MMRM). Baseline was defined as the average of recorded morning and evening asthma symptom scores over the 7 days before randomization. Daytime Scores range from 0=No symptoms during the day to 5=Symptoms so severe that I could not go to work or perform normal daily activities; Nighttime Scores range from 0=No symptoms during the night to 4=Symptoms so severe that I did not sleep at all. The daily asthma symptom score was therefore 0 - 9 with 0=no symptoms during the day or night and 9=severe symptoms both day and night.

Time frame:
Day 1 (baseline), weeks 1-12
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Weekly Average of the Total Daily Asthma Symptom Score Over Weeks 1-12
units on a scalePlacebo BAI and MDIBDP 80 mcg BAIBDP 160 mcg BAIBDP 80 mcg MDIBDP 160 mcg MDI
Change From Baseline in the Weekly Average of the Total Daily Asthma Symptom Score Over Weeks 1-12-0.27 ± 0.036-0.44 ± 0.036-0.36 ± 0.036-0.31 ± 0.036-0.36 ± 0.036
Statistical analysis
  • Placebo BAI and MDI vs BDP 80 mcg BAI · Mixed Models Analysis · p = 0.0011 · Mean difference (final values): -0.16 · 95% CI -0.261 to -0.065
  • Placebo BAI and MDI vs BDP 160 mcg BAI · Mixed Models Analysis · p = 0.0869 · Mean difference (final values): -0.09 · 95% CI -0.185 to 0.013
  • Placebo BAI and MDI vs BDP 80 mcg MDI · Mixed Models Analysis · p = 0.4388 · Mean difference (final values): -0.04 · 95% CI -0.138 to 0.060
  • Placebo BAI and MDI vs BDP 160 mcg MDI · Mixed Models Analysis · p = 0.1041 · Mean difference (final values): -0.08 · 95% CI -0.180 to 0.017
SecondaryKaplan-Meier Estimates For Time to Withdrawal Due to Meeting Stopping Criteria for Worsening Asthma During the 12-week Treatment Period

Time to withdrawal due to meeting stopping criteria was defined as number of days elapsed from the date of first dose of double-blind study treatment to the date of withdrawal due to meeting stopping criteria. Kaplan-Meier estimates (median and 95% CI of the median) are not applicable if the proportion of participants withdrawn is less than 0.5.

Time frame:
Day 1 to 12 weeks
Reported as:
Median · Days
Kaplan-Meier Estimates For Time to Withdrawal Due to Meeting Stopping Criteria for Worsening Asthma During the 12-week Treatment Period
DaysPlacebo BAI and MDIBDP 80 mcg BAIBDP 160 mcg BAIBDP 80 mcg MDIBDP 160 mcg MDI
Kaplan-Meier Estimates For Time to Withdrawal Due to Meeting Stopping Criteria for Worsening Asthma During the 12-week Treatment PeriodNA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Placebo BAI and MDI vs BDP 80 mcg BAI · Log Rank · p = 0.2870
  • Placebo BAI and MDI vs BDP 160 mcg BAI · Log Rank · p = 0.5257
  • Placebo BAI and MDI vs BDP 80 mcg MDI · Log Rank · p = 0.9982
  • Placebo BAI and MDI vs BDP 160 mcg MDI · Log Rank · p = 0.7633

Adverse events

Collected over - Run-In: Days -21 to Day 0 - Double-blind Study Treatment: Day 1 to Week 12. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Run-in Placebo—0/628 (0%)1/628 (0.2%)
Placebo BAI and MDI—0/127 (0%)8/127 (6.3%)
BDP 80 mcg BAI—0/126 (0%)6/126 (4.8%)
BDP 160 mcg BAI—0/125 (0%)13/125 (10.4%)
BDP 80 mcg MDI—0/125 (0%)15/125 (12%)
BDP 160 mcg MDI—0/125 (0%)11/125 (8.8%)
Most frequent other events
Most frequent other events
EventRun-in PlaceboPlacebo BAI and MDIBDP 80 mcg BAIBDP 160 mcg BAIBDP 80 mcg MDIBDP 160 mcg MDI
NasopharyngitisInfections and infestations0/6284/1275/12611/1256/1256/125
CoughRespiratory, thoracic and mediastinal disorders1/6284/1271/1263/1259/1256/125

Baseline characteristics

Intent to treat (ITT) population

Age, Continuous
Age, Continuous(years)Placebo BAI and MDIBDP 80 mcg BAIBDP 160 mcg BAIBDP 80 mcg MDIBDP 160 mcg MDITotal
Mean8.2 ± 2.068.5 ± 2.108.4 ± 1.248.2 ± 1.788.4 ± 1.868.3 ± 1.93
Sex: Female, Male
Sex: Female, Male(Participants)Placebo BAI and MDIBDP 80 mcg BAIBDP 160 mcg BAIBDP 80 mcg MDIBDP 160 mcg MDITotal
Female4152464950238
Male8674797675390
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo BAI and MDIBDP 80 mcg BAIBDP 160 mcg BAIBDP 80 mcg MDIBDP 160 mcg MDITotal
American Indian or Alaska Native3443115
Asian022004
Native Hawaiian or Other Pacific Islander000000
Black or African American4234333749195
White7169697663348
More than one race000000
Unknown or Not Reported11171791266
08

Study locations

102 sites
  • Teva Investigational Site 12346
    Hoover, Alabama, United States
  • Teva Investigational Site 12294
    Montgomery, Alabama, United States
  • Teva Investigational Site 10925
    Phoenix, Arizona, United States
  • Teva Investigational Site 12349
    Little Rock, Arkansas, United States
  • Teva Investigational Site 10903
    Costa Mesa, California, United States
  • Teva Investigational Site 10911
    Downey, California, United States
  • Teva Investigational Site 10901
    Huntington Beach, California, United States
  • Teva Investigational Site 12297
    Huntington Beach, California, United States
  • Teva Investigational Site 10880
    Mission Viejo, California, United States
  • Teva Investigational Site 10895
    Orange, California, United States
  • Teva Investigational Site 10924
    Paramount, California, United States
  • Teva Investigational Site 10910
    Rolling Hills Estates, California, United States
  • Teva Investigational Site 12343
    Roseville, California, United States
  • Teva Investigational Site 12298
    San Diego, California, United States
  • Teva Investigational Site 12300
    San Diego, California, United States
  • Teva Investigational Site 12295
    San Jose, California, United States
  • Teva Investigational Site 12312
    West Covina, California, United States
  • Teva Investigational Site 10937
    Centennial, Colorado, United States
  • Teva Investigational Site 10899
    Colorado Springs, Colorado, United States
  • Teva Investigational Site 10894
    Aventura, Florida, United States
  • Teva Investigational Site 12335
    Gainesville, Florida, United States
  • Teva Investigational Site 12336
    Homestead, Florida, United States
  • Teva Investigational Site 12345
    Homestead, Florida, United States
  • Teva Investigational Site 12315
    Miami, Florida, United States
  • Teva Investigational Site 12341
    Miami, Florida, United States
  • Teva Investigational Site 12342
    Miami, Florida, United States
  • Teva Investigational Site 10919
    Orlando, Florida, United States
  • Teva Investigational Site 12281
    Sarasota, Florida, United States
  • Teva Investigational Site 12332
    Winter Park, Florida, United States
  • Teva Investigational Site 10935
    Gainesville, Georgia, United States
  • Teva Investigational Site 10912
    Lawrenceville, Georgia, United States
  • Teva Investigational Site 10927
    Savannah, Georgia, United States
  • Teva Investigational Site 10885
    Owensboro, Kentucky, United States
  • Teva Investigational Site 12317
    Covington, Louisiana, United States
  • Teva Investigational Site 12296
    Baltimore, Maryland, United States
  • Teva Investigational Site 12323
    White Marsh, Maryland, United States
  • Teva Investigational Site 10897
    North Dartmouth, Massachusetts, United States
  • Teva Investigational Site 10932
    Ypsilanti, Michigan, United States
  • Teva Investigational Site 10914
    Plymouth, Minnesota, United States
  • Teva Investigational Site 10917
    Columbia, Missouri, United States
  • Teva Investigational Site 10916
    Rolla, Missouri, United States
  • Teva Investigational Site 12331
    Missoula, Montana, United States
  • Teva Investigational Site 10922
    Brick, New Jersey, United States
  • Teva Investigational Site 10909
    Ocean City, New Jersey, United States
  • Teva Investigational Site 12289
    Verona, New Jersey, United States
  • Teva Investigational Site 10939
    Asheville, North Carolina, United States
  • Teva Investigational Site 12348
    Charlotte, North Carolina, United States
  • Teva Investigational Site 10893
    Raleigh, North Carolina, United States
  • Teva Investigational Site 10888
    Canton, Ohio, United States
  • Teva Investigational Site 12302
    Fairfield, Ohio, United States
  • Teva Investigational Site 10921
    Toledo, Ohio, United States
  • Teva Investigational Site 12285
    Toledo, Ohio, United States
  • Teva Investigational Site 10906
    Oklahoma City, Oklahoma, United States
  • Teva Investigational Site 10915
    Oklahoma City, Oklahoma, United States
  • Teva Investigational Site 12314
    Oklahoma City, Oklahoma, United States
  • Teva Investigational Site 10891
    Tulsa, Oklahoma, United States
  • Teva Investigational Site 10892
    Medford, Oregon, United States
  • Teva Investigational Site 10898
    Portland, Oregon, United States
  • Teva Investigational Site 12273
    Pittsburgh, Pennsylvania, United States
  • Teva Investigational Site 12282
    Warwick, Rhode Island, United States
  • Teva Investigational Site 10902
    North Charleston, South Carolina, United States
  • Teva Investigational Site 10938
    Orangeburg, South Carolina, United States
  • Teva Investigational Site 12347
    Beaumont, Texas, United States
  • Teva Investigational Site 10926
    Boerne, Texas, United States
  • Teva Investigational Site 10908
    Dallas, Texas, United States
  • Teva Investigational Site 10918
    Dallas, Texas, United States
  • Teva Investigational Site 12291
    El Paso, Texas, United States
  • Teva Investigational Site 12329
    Live Oak, Texas, United States
  • Teva Investigational Site 10890
    New Braunfels, Texas, United States
  • Teva Investigational Site 10904
    San Antonio, Texas, United States
  • Teva Investigational Site 10929
    San Antonio, Texas, United States
  • Teva Investigational Site 10879
    Waco, Texas, United States
  • Teva Investigational Site 10883
    Richmond, Virginia, United States
  • Teva Investigational Site 10886
    Bellingham, Washington, United States
  • Teva Investigational Site 10913
    Greenfield, Wisconsin, United States
  • Teva Investigational Site 60017
    Cakovec, Croatia
  • Teva Investigational Site 60018
    Zagreb, Croatia
  • Teva Investigational Site 60019
    Zagreb, Croatia
  • Teva Investigational Site 21037
    Guadalajara, Mexico
  • Teva Investigational Site 21042
    Guadalajara, Mexico
  • Teva Investigational Site 21039
    Mexico City, Mexico
  • Teva Investigational Site 21045
    Mexico City, Mexico
  • Teva Investigational Site 21035
    Monterrey, Mexico
  • Teva Investigational Site 21043
    San Lucas Tepetlacalco, Mexico
  • Teva Investigational Site 21047
    San Lucas Tepetlacalco, Mexico
  • Teva Investigational Site 21051
    Zapopan, Mexico
  • Teva Investigational Site 53276
    Bialystok, Poland
  • Teva Investigational Site 53267
    Krakow, Poland
  • Teva Investigational Site 53269
    Lodz, Poland
  • Teva Investigational Site 53272
    Lodz, Poland
  • Teva Investigational Site 53271
    Lublin, Poland
  • Teva Investigational Site 53274
    Lublin, Poland
  • Teva Investigational Site 53273
    Tarnow, Poland
  • Teva Investigational Site 53275
    Wroclaw, Poland
  • Teva Investigational Site 53270
    Zawadzkie, Poland
  • Teva Investigational Site 58165
    Dnipropetrovsk, Ukraine
  • Teva Investigational Site 58171
    Kharkiv, Ukraine
  • Teva Investigational Site 58168
    Kryvyi Rih, Ukraine
  • Teva Investigational Site 58167
    Kyiv, Ukraine
  • Teva Investigational Site 58172
    Kyiv, Ukraine

Showing the first 100 of 102 sites across 5 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Vandewalker M, Hickey L, Small CJ. Efficacy and safety of beclomethasone dipropionate breath-actuated or metered-dose inhaler in pediatric patients with asthma. Allergy Asthma Proc. 2017 Sep 14;38(5):354-364. doi: 10.2500/aap.2017.38.4078. Epub 2017 Jul 14. PubMed 28710850 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2013, a primary completion of Feb 2016 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2018, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2014
First posted
Jan 20, 2014
Start
Dec 2013
Primary completionActual
Feb 2016
CompletionActual
Mar 2016
Results first posted
Feb 12, 2018
Last update
Nov 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02040766
Responsible party
Sponsor
First posted
Jan 20, 2014
Start date
Dec 2013
Primary completion
Feb 2016
Completion
Mar 2016
Results posted
Feb 12, 2018
Last update
Nov 9, 2021

Study contacts

Teva Medical Expert, MD
study director · Teva Branded Pharmaceutical Products R&D, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Beclomethasone

Start the discussion